| References: |
Description of Cabozantinib: Cabozantinib (XL 184) is an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several tyrosine receptor kinases. Specifically, cabozantinib appears to have a strong affinity For the hepatocyte growth factor receptor (Met) and vascular endothelial growth factor receptor 2 (VEGFR2), which may result in inhibition of tumor growth and angiogenesis, and tumor regression. This agent has also been shown to inhibit mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (Flt3) and tyrosine-protein kinase receptor (Tie-2). Check For active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).
For the detailed information about the solubility of XL-184 (Cabozantinib, BMS907351) in water, the solubility of XL-184 (Cabozantinib, BMS907351) in DMSO, the solubility of XL-184 (Cabozantinib, BMS907351) in PBS buffer, the animal experiment（test） of XL-184 (Cabozantinib, BMS907351), the in vivo,in vitro and clinical trial test of XL-184 (Cabozantinib, BMS907351), the cell experiment（test） of XL-184 (Cabozantinib, BMS907351), the IC50, EC50 and Affinity of XL-184 (Cabozantinib, BMS907351) , please contact DC Chemicals. |
